DPD for 5-fluorouracil toxicity
Fluoropyrimidines (5-fluorouracil, capecitabine and tegafur) are chemotherapy drugs used to treat certain cancers. Treatment with fluoropyrimidines is generally well tolerated. However, 3-6% of patients suffer serious adverse drug reactions as a result of genetic variation in their DPYD gene which means they are unable to properly metabolise and breakdown these drugs. Genetic testing for the common DPYD genetic variants is recommended in some cancer patients.
Testing for common DPYD polymorphisms is available via the Genomic Medicine Service Cancer Test Directory following the publication of the Clinical Commissioning Urgent Policy Statement Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies. Testing is centrally commissioned and available from the East Genomic Laboratory Hub.
Order a Test
The Cambridge Genomic Laboratory at Cambridge University Hospitals provides DPYD testing for the East GLH region. To ensure a rapid service, please submit samples directly to the laboratory by first class post or courier.
Important: Please use our DPYD referral form and include information regarding the patients clinical indication and a routinely monitored secure email address for return of results.